Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.
Medicare Insights
Through an integrated medical, pharmacy, claims and legal approach, we deliver insights to help navigate the ever‑changing Medicare Secondary Payer landscape.
Recent blog posts
|
August 23, 2023 · Medicare Insights Team
On August 8, the Center for Medicare & Medicaid Services (CMS) released an updated Non-Group Health Plan (NGHP) User Guide, Version 7.2, which includes important updates. Read more... |
|
July 18, 2023 · Clinical Team
The 2Q 2023 Brand-Generic Pipeline update Read more... |
|
|
July 06, 2023 · Clinical Team
Extended-release Brixadi has been approved by the FDA for subcutaneous injection in patients recovering from Opioid Use Disorder as part of their treatment plan. Read more... |
|
|
June 13, 2023 · Medicare Insights Team
On June 6, the Center for Medicare & Medicaid Services (CMS) released an updated Non-Group Health Plan (NGHP) User Guide, Version 7.2, which includes important changes. Read more... |
|
|
May 19, 2023 · Medicare Insights Team
The Centers for Medicare and Medicaid Services (CMS) released an updated Workers’ Compensation Medicare Set Aside (WCMSA) Reference Guide, version 3.9, dated 5/15/2023, which includes two significant changes. Read more... |
|
|
May 18, 2023 · Medicare Insights Team
On April 27, 2023, CMS released the NGHP Applicable Plan Appeals Reference Guide as a way to streamline the appeal process, which includes types of appeals and documentation needed to support appeals. Read more... |
|
|
May 08, 2023 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Teva Pharmaceuticals USA voluntarily recalled specific lots of various strengths of fentanyl buccal tablets at the consumer level. Read more... |
|
|
May 02, 2023 · Clinical Team
On March 29, 2023, the U.S. Food and Drug Administration (FDA) approved Narcan® (naloxone hydrochloride) 4 mg Nasal Spray for over-the-counter (OTC), nonprescription, use. Read more... |
Page 2 of 6
